1Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638-3646. https://doi.org/10.1200/jco.2017.75.6155
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884. http://dx.doi.org/10.1200/JCO.2017.73.7585
4Huang CS, Toi M, Im YH, et al. Abemaciclib plus fulvestrant in east Asian women with HR+, HER2- advanced breast cancer: overall survival from MONARCH 2. Paper presented at: 1st European Society for Medical Oncology (ESMO) Asia Virtual Congress; November 20-22, 2020. Accessed November 17, 2020. https://oncologypro.esmo.org/meeting-resources/esmo-asia-virtual-congress-2020/abemaciclib-plus-fulvestrant-in-east-asian-women-with-hr-her2-advanced-breast-cancer-overall-survival-from-monarch-2
5Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218-5224. http://dx.doi.org/10.1158/1078-0432.CCR-17-0754
6Zhang QY, Sun T, Yin YM, et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020;12:1-14. https://doi.org/10.1177/1758835920963925
7Jiang Z, Hu X, Zhang Q, et al. Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: analysis of the MONARCH plus study. Paper presented at: 43rd Annual San Antonio Breast Cancer Symposium (SABCS); December 8-11, 2020; San Antonio, TX. Accessed November 17, 2020. Abstract PS13-25 https://www.sabcs.org/Portals/SABCS2016/2020%20SABCS/ALL%20ABSTRACTS%202-9.pdf?ver=2020-12-09-104626-337
8Hu X, Yang N, Zhang J, et al. A phase 1 study of abemaciclib in Chinese patients with advanced and/or metastatic cancers. Poster presented at: 111th Annual Meeting of the American Association for Cancer Research (AACR Virtual); June 22-24, 2020. Accessed May 15, 2020. https://www.abstractsonline.com/pp8/#!/9045/presentations/abemaciclib/1
9Omori Y, Enatsu S, Cai Z, et al. Patients’ preferences for postmenopausal HR+ HER2- advanced breast cancer treatments in Japan. Poster presented at: 41st Annual San Antonio Breast Cancer Symposium (SABCS); December 4-8, 2018; San Antonio, TX. https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_545&terms=